The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | Is transplantation superior to CAR-T therapy in multiple myeloma?
Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the drawbacks of CAR-T therapy over transplantation in patients with multiple myeloma. Whilst CAR-Ts are typically assessed in heavily pre-treated patients, ongoing head-to-head studies will compare CAR-Ts against transplantation. Overall, patients receiving melphalan will have a more durable response and are less likely to progress on melphalan. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
